Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 8:40 a.m. EDT.
STAMFORD, Conn., April 02, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April ...
STAMFORD, Conn., March 07, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a virtual key opinion leader (KOL) event titled “Meet the NP Experts” on Wednesday, March 27, 2024, at 10:00 a.m. EDT.
Cara Therapeutics, Inc. (NASDAQ:CARA ) Q4 2023 Earnings Call Transcript March 4, 2024 4:30 PM ET Company Participants Matt Murphy - Manager, IR Chris Posner - CEO Ryan Maynard - CFO Joana Goncalves - CMO Conference Call Participants Annabel Samimy - Stifel Joseph Stringer - Needham & Company Dennis Ding - Jefferies David Amsellem - Piper Sandler Operator Thank you for standing by, and welcome t...
While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks. Of course, the excitement goes toward both extremes of the emotional spectrum.
STAMFORD, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) today announced the Company will host a conference call and live audio webcast on Monday, March 4, 2024, at 4:30 p.m. EST to report fourth quarter and full year 2023 financial results and provide a corporate update.
Cara Therapeutics (NASDAQ: CARA ) layoffs are coming for up to 50% of the biopharmaceutical company's employees as it shifts focus to its late-stage notalgia paresthetica program. Cara Therapeutics notes that this will see it give more attention to its oral difelikefalin Phase 2/3 clinical program.
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.